Natera Secures 30% Ongoing Royalty in MRD Patent Dispute — Natera, Inc.

Event summary

U.S. District Court in Delaware ordered a 30% ongoing royalty to Natera on post-injunction revenues from infringing MRD-related product sales.
The jury had previously awarded an effective royalty of 20.5% on pre-injunction revenues, which remains unchanged.
The court upheld the validity of all three asserted MRD patents and preserved damages related to Invitae’s MRD-related products.
Natera has over 650 issued or pending patents, including a strong portfolio of MRD patents.

The big picture

This decision reinforces Natera’s strong position in the precision medicine space, particularly in minimal residual disease (MRD) testing. The ongoing royalty underscores the value of Natera’s intellectual property and could set a precedent for future patent disputes in the biotechnology sector. The ruling also highlights the competitive tensions in the cell-free DNA market, where patent protection is critical for maintaining technological advantages.

What we're watching

Royalty Impact: How the 30% ongoing royalty will affect Natera’s revenue and profitability moving forward.
Competitive Dynamics: Whether ArcherDx and Invitae can sustain their market positions amid patent infringement penalties.
Patent Portfolio Strength: The pace at which Natera can leverage its extensive patent portfolio to secure additional licensing deals or litigation wins.